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Background: Bisphosphonates have a high adsorption on calcified tissues and are
commonly used in the treatment of bone disorder diseases. Conjugates of
bisphosphonates with macrocyclic chelators open new possibilities in bone targeted
radionuclide imaging and therapy. Subsequent to positron emission tomography
(PET) examinations utilizing 68Ga-labelled analogues, endoradiotheraphy with 177Lu-
labelled macrocyclic bisphosphonates may have a great potential in the treatment of
painful skeletal metastases.
Methods: Based on the established pharmaceuticals pamidronate and
zoledronate two new DOTA-α-OH-bisphosphonates, DOTAPAM and DOTAZOL(MM1.
MZ) were successfully synthesized. The ligands were labelled with the positron
emitting nuclide 68Ga and the β- emitting nuclide 177Lu and compared in
in vitro studies and in ex vivo biodistribution studies together with small animal
PET and single photon emission computed tomography (SPECT) studies against
[18F]NaF and a known DOTA-α-H-bisphosphonate conjugate (BPAPD) in healthy
Wistar rats.
Results: The new DOTA-bisphosphonates can be labelled in high yield of 80 to
95 % in 15 min with post-processed 68Ga and >98 % with 177Lu. The tracers
showed very low uptake in soft tissue, a fast renal clearance and a high
accumulation on bone. The best compound was [68Ga]DOTAZOL (SUV Femur = 5.4
± 0.6) followed by [18F]NaF (SUV Femur = 4.8 ± 0.2), [
68Ga]DOTAPAM (SUV Femur = 4.5
± 0.2) and [68Ga]BPAPD (SUV Femur = 3.2 ± 0.3). [
177Lu]DOTAZOL showed a similar
distribution as the diagnostic 68Ga complex.
Conclusion: The 68Ga labelled compounds showed a promising
pharmacokinetics, with similar uptake profile and distribution kinetics. Bone
accumulation was highest for [68Ga]DOTAZOL, which makes this compound
probably an interesting bone targeting agent for a therapeutic approach with
177Lu. The therapeutic compound [177Lu]DOTAZOL showed a high target-to-
background ratio. SPECT experiments showed concordance to the PET scans in
healthy rats. [68Ga/177Lu]DOTAZOL appears to be a potential theranostic
combination in the management of disseminated bone metastases.
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Radionuclide bone scintigraphy is usually applied to locate skeletal lesions from various
cancer origins. The findings of the scintigraphy reflect the status of metabolic activity
of the bone tissue as a result of tumour invasion. Positron emission tomography (PET)
has one of the highest diagnostic sensitivity and specificity for the detection of skeletal
metastases (Hamaoka et al. 2004), when used with the cyclotron produced [18F]NaF.
Actually more common is the use of 99mTc-bisphosphonate compounds in the whole
body scintigraphy (Evan-Sapir et al. 2006). The positron emitter 68Ga has several advan-
tages, which makes it an interesting object in the development of radiopharmaceuticals.
First of all it is the cyclotron independent availability based on the 68Ge/68Ga generator
system—similar to the availability of 98mTc, and second, it is the intense emission of
positrons—similar to 18F. Finally, it is the principle of the bifunctional chelating agent
to design radiometal, in particular *Me(III), based pharmaceuticals. Substitution of β+
by β- or α-particle emitters leads in principle to a theranostic concept, wherein diagno-
sis and therapy is combined in one precursor molecule. Since bisphosphonates (BP)
show a high adsorption rate on bone, a number of new DOTA (1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid) based bone targeting molecules were described in
the literature (Ogawa & Saji 2011), including conjugates of alendronic acid (Ogawa
et al. 2009) (4-aminobutyl-1-hydroxy-1,1-bis[phosphonic acid]) and other α-H-
bisphosphonates (Vitha et al. 2008). First promising human applications reported for
[68Ga]BPAMD showed PET scans of equal quality to [18F]NaF and particularly a higher
SUVmax in seleceted bone lesions (Fellner et al. 2010). In addition Passah et al. reported
the use of a bisphosphonate conjugated to NOTA (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid) chelator to detect bone metastases efficiently (Passah et al.
2014; Pfannkuchen et al. 2015).
The evolution of modern osteoporosis drugs went from α-H bisphosphonates to α-
OH and N-heteroaromatic bisphosphonates (Russell et al. 2008). Actually, the synthesis
of DOTA-conjugated α-OH-bisphosphonates is more difficult compared to DOTA-
conjugated α-H-bisphosphonates. But DOTA-α-OH-bisphosphonates may have higher
skeletal retentions compared to DOTA-α-H-bisphosphonates. Consequently, we
synthesized a pamidronate (3-aminopropyl-1-hydroxy-1,1-bis[phosphonic acid]) and a
zoledronate derivative (([1-hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic
acid) as DOTA conjugates (Chart 1), labelled both with 68Ga and compared them in
in vivo small animal PET and in ex vivo organ distribution studies in healthy Wistar
rats with the known DOTA-α-H-bisphosphonate of similar structure (BPAPD) (for
structures see Chart 1) and with [18F]NaF. Since DOTA offers the possibility of stable
complexation of various radiometals, including isotopes relevant to therapy, the com-
pounds discussed in this manuscript are potential precursors for a theranostic treat-
ment of metabolic bone disorders, like skeletal metastases. Therefore, the bestChart 1 Structure of discussed DOTA-bisphosphonates
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organ distribution studies ex vivo and in small animal SPECT imaging studies in vivo
in healthy Wistar rats.Results
Synthesis
Synthesis of BPAPD is published in the literature (Vitha et al. 2008) as well as the syn-
thesis of pamidronate (Kieczykowski et al. 1995). Compound (4) was prepared by a
standard method for the synthesis of hydroxyl-bisphosphonates from carboxylic acids
(Widler et al. 2002). The cleavage of the amide to form the primary amine was achieved
in the same step, based on the strong acidic condition after hydrolysis of phosphorus
trichloride. The imidazole derivative (3) was obtained from ω-N-acetylhistamine (1)
after alkylation with benzyl bromoacetate and hydrogenation. Only the 1,4-(H-2 and H-
5) imidazole (2) was formed during this reaction. A convenient method to discriminate
between the 1,4- and the 1,5-alkylation product is described in the literature by the dif-
ferent coupling constants of the aromatic imidazole ring protons (Amino et al. 1989).
(2) showed a coupling constant of J2,5 = 1.3 Hz, which is characteristic for the 1,4-prod-
uct (range from 1.1 to 1.5 Hz). The final conjugation of the hydroxy-bisphosphonates
(DOTAPAM and DOTAZOL) was performed via a modified route described by Ogawa
et al. (2009). The compounds were first purified by preparative HPLC workup, and the
remaining DOTA impurities were removed by solid phase extraction (SPE) using a
weak anion exchanger resin (Scheme 1).Radiolabelling with n.c.a. 68Ga and n.c.a. 177Lu as well as quality control
Labelling with n.c.a. 68Ga was performed in sodium acetate buffer under heating (95 °
C) on a thermo shaker for 15 min. Radiochemical yields (RCY) of the 68Ga-DOTA-bis-
phosphonate complexes were in the range between 80 and 95 %. After SPE using again
a weak anion exchanger, the labelled compounds were present in 2 mL phosphate buff-
ered saline (PBS) with a purity of over 98 %, ready for injection. Yields and purities
were measured by radio thin layer chromatography (TLC) and HPLC (Additional file 1:
Figure S1). For this HPLC quality controls aliquots of the purified reaction solutions
were quenched with desferoxamine (DFO). Uncomplexed 68Ga remaining was instantly
trapped by DFO to form [68Ga]DFO, which could be discriminated on RP-HPLC fromScheme 1 Synthesis of DOTAZOL: (i) benzyl bromoacetate, DMF, Cs2CO3, 0 °C, 12 h. (ii) H2, Pd/C, MeOH, RT,
24 h. (iii) 1. PCl3 ,H3PO3, MeSO3H, 75 °C, 12 h, 2. H2O, 105 °C, 24 h. (iv) DOTA-NHS-ester, Na2CO3, 40 °C, 24 h
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the radio labelled 68Ga-DOTA-bisphosphonates showed no retention on common RP-
HPLC columns when using acetronitrile/water mixtures as solvents. Therefore, the
radio HPLC method was further developed for the Lu-177 analogous using an ion pair
reagent as running buffer. The method was later successfully adapted for the Ga-68
complexes (further details about radio-HPLC please refer to Additional file 1 section).
Quantitative complexation of 177Lu(III) with DOTAZOL was obtained within 30 min at
98 °C. Radiochemicals yields were determined by radio-TLC and radio-HPLC.Adsorption experiments on apatite
Simple adsorption experiments on hydroxy apatite (HAP) proved the high accumula-
tion of the 68Ga-labelled compounds on calcified surfaces like bone tissue, while
[68Ga]DOTA as a control showed almost no adsorption. The hydroxy bisphosphonates
[68Ga]DOTAPAM (91.2 ± 2.7 %) and [68Ga]DOTAZOL (92.7 ± 1.3 %) showed an identical
accumulation in this experiment (Fig. 1). Thus, binding of the pamidronate and zole-
dronate conjugates was superior compared to the α-H-bisphosphonate [68Ga]BPAPD
(83.0 ± 0.8 %).Ex vivo biodistribution: 68Ga
The results of the ex vivo organ distribution in healthy Wistar rats of [68Ga]DOTAPAM,
[68Ga]DOTAZOL, [68Ga]BPAPD and [18F]NaF are presented in Tables 1 and 2, respect-
ively. All 68Ga-labelled bisphosphonate compounds showed high accumulation in bone
and low uptake in soft tissue. After 60 min the estimated activity in the skeleton was in
the range of 40 to 50 % of the injected dose (ID) for [68Ga]BPAPD (38.8 ± 5.0 %ID),
[68Ga]DOTAPAM (48.4 ± 4.7 %ID) and [68Ga]DOTAZOL (42.7 ± 5.2 %ID), which is com-
parable to that of [18F]NaF (43.7 ± 1.9 %ID). Compared to the bisphosphonates,
[18F]NaF showed a slight faster renal clearance and an overall lower concentration of
activity in other organs, besides the bone. The bone-to-blood ratio determined from
biodistribution were 3.7 for [68Ga]BPAPD, 7.6 for [68Ga]DOTAPAM, 11.5 for [68Ga]DO-
TAZOL and 97.4 for [18F]NaF.Fig. 1 Adsorption of the three 68Ga-labelled DOTA-bisphosphonates on 20 mg HAP after 10 min incubation
time, compared to [68Ga]DOTA shown in percent of the adsorbed fraction (N = 5)
Table 1 Ex vivo biodistribution of [68Ga]DOTAPAM, [68Ga]DOTAZOL, [68Ga]BPAPD and [18F]NaF in
healthy Wistar rats after 60 min p. i
Organ [68Ga]DOTAPAM [68Ga]DOTAZOL [68Ga]BPAPDa [18F]NaFa
Lung 0.53 (0.16) b 0.45 (0.11) b 0.43 (0.08) 0.05 (0.01)
Liver 0.43 (0.04) b,d 0.28 (0.03) b,d 0.37 (0.11) 0.03 (0.01)
Spleen 0.31 (0.04) b,d 0.17 (0.02) b,d 0.23 (0.08) 0.13 (0.20)
Kidneys 0.48 (0.06) b 0.53 (0.04) b 0.56 (0.08) 0.11 (0.01)
Muscle 0.09 (0.02) c 0.08 (0.02) c 0.17 (0.02) 0.06 (0.05)
Heart 0.23 (0.02) b,c,d 0.14 (0.04) b,c,d 0.32 (0.09) 0.02 (0.01)
Blood 0.60 (0.03) b,c 0.47 (0.19) b,c 0.86 (0.21) 0.05 (0.01)
Intestine 0.28 (0.12) b 0.14 (0.08) b 0.26 (0.05) 0.02 (0.01)
Femur 4.53 (0.17) c,d 5.40 (0.62) c,d 3.21 (0.29) 4.87 (0.32)
Data are expressed in SUV. Each value represents the mean (S.D.) for five animals
a Data taken from (Meckel et al. 2013)
b P < 0.05 vs. [18F]NaF
c P < 0.05 vs. [68Ga]BPAPD
d P < 0.05 [68Ga]DOTAPAM vs. [68Ga]DOTAZOL
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Uptake kinetics and images from in vivo μPET studies are presented in Fig. 2. [68Ga]B-
PAPD, [68Ga]DOTAPAM and [68Ga]DOTAZOL showed a rapid bone accumulation,
reaching a plateau level at 45 min p. i. and a fast blood elimination. Distribution kinet-
ics as time activity curves, Figs. 2 and 3, are very similar for all 68Ga-tracers. Variation
in the kidney profile might be a result of differing response of the rats to anesthesia
and diverging kidney activity. After 60 min all 68Ga-labelled bisphosphonates gave
clearly visible bone scans. [18F]NaF PET showed in small animals a slight better quality
and resolution.Ex vivo biodistribution: 177Lu
Because [68Ga]DOTAZOL appeared to be the compound with the highest bone accumu-
lation among all the 68Ga-bisphosphonates studied in this manuscript, the 177Lu-analo-
que compound was investigated. The results of the organ distribution of [177Lu]
DOTAZOL are represented in Table 3. The compound showed fast and high uptake in
the skeleton and low accumulation in soft tissue. [177Lu]DOTAZOL showed the same
skeletal retention as [68Ga]DOTAZOL. Blood activity was lower for the 177Lu-complex,
but renal clearance time showed to be longer. The activity in the skeleton was constant
for 8 days, which clearly reveals the long biological half-life of [177Lu]DOTAZOL in theTable 2 Bone-to-blood ratios and calculated total activity in the skeleton in healthy Wistar rats, at
60 min p. i. of [68Ga]DOTAPAM, [68Ga]DOTAZOL, [68Ga]BPAPD and [18F]NaF
compound %ID in skeleton (S.D.) bone to blood ratio
[68Ga]DOTAPAM 48.4 (4.7) 7.6
[68Ga]DOTAZOL 42.7 (5.2) 11.5
[68Ga]BPAPDa 38.3 (5.0) 3.7
[18F]NaFa 43.7 (1.9) 97.4
Each value represents the mean for five animals
aData taken from (Meckel et al. 2013)
Fig. 2 MIP (maximum intensity projection) in the thorax region of Wistar rats after 60 min p.i. and time
activity curves (TAC) of [68Ga]BPAPD and [18F]NaF
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samples over 1 h (radio-HPLC in Additional file 1: Figure S3).In vivo evaluation: 177Lu
SPECT image of [177Lu]DOTAZOL is exemplified in Fig. 5. The images show a good tar-
get to soft tissue ratio (49) with high skeletal accumulation (3.43 ± 0.40 %ID/g) and low
background activity (blood: 0.07 ± 0.01 %ID/g; muscle: 0.02 ± 0.00 %ID/g).Discussion
The synthetic route for the DOTA-α-OH-bisphosphonate derivatives is distinctly differ-
ent from that of the compound BPAPD. As a consequence, the α-H-bisphosphonateFig. 3 MIP (maximum intensity projection) in the thorax region of Wistar rats after 60 min p.i. and time
activity curves (TAC) of [68Ga]DOTAPAM and [68Ga]DOTAZOL
Table 3 Ex vivo biodistribution of [177Lu]DOTAZOL in healthy Wistar rats after 1 h, 1 and 8 days p.i. ,
expressed in terms of %ID per organ and per gram tissue, respectively
Organ % ID per Organ % ID per gram
1 h 24 h 8 d 1 h 24 h 8 d
Lung 0.06 (0.01) 0.01 (0.00) 0.00 (0.00) 0.08 (0.02) 0.01 (0.01) 0.00 (0.00)
Liver 0.40 (0.13) 0.21 (0.07) 0.24 (0.04) 0.09 (0.04) 0.02 (0.01) 0.03 (0.01)
Spleen 0.01 (0.00) 0.01 (0.00) 0.01 (0.00) 0.05 (0.01) 0.02 (0.02) 0.02 (0.01)
Kidneys 1.78 (0.13) 1.64 (0.20) 0.10 (0.02) 1.70 (0.13) 1.25 (0.11) 0.07 (0.01)
Muscle 0.04 (0.02) 0.00 (0.00) 0.00 (0.00) 0.02 (0.00) 0.00 (0.00) 0.00 (0.00)
Heart 0.02 (0.00) 0.00 (0.00) 0.00 (0.00) 0.04 (0.01) 0.00 (0.00) 0.00 (0.00)
Blood 0.56 (0.07) 0.00 (0.00) 0.00 (0.00) 0.07 (0.01) 0.00 (0.00) 0.00 (0.00)
Intestine 1.59 (0.13) 0.38 (0.25) 0.29 (0.21) 0.08 (0.03) 0.02 (0.02) 0.02 (0.02)
Femur 2.11 (0.22) 1.89 (0.11) 2.25 (0.11) 3.43(0.41) 3.20 (0.40) 3.03 (0.17)
Skeleton 44.62 (5.00) 44.79 (4.82) 44.78 (3.71) - - -
Each value represents the mean (S.D.) for four animals
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the pamidronate or imidazole moiety in water via the N-hydroxysuccinimide ester of
DOTA results in lower yields and the formation of problematic side products from
ester hydrolysis, which have to be removed. Ogawa et al. (2009) separated the
[90Y]DOTA-alendronate derivative from [90Y]DOTA by semipreparative HPLC. A com-
bination of semipreparative HPLC and SPE showed the best purification results after
the amide formation. Other groups reported the synthesis of protected alendronate,
where the hydroxy bisphosphonate part is esterified by ethyl groups and a tert-butyldi-
methylsilyl ether (Vachal et al. 2006), leading to a new route for the developing of che-
lator α-OH- bisphosphonate conjugates (Suzuki et al. 2011). Nevertheless, this reaction
seemed to be limited for compounds like alendronate. We were not able to prepare
other derivatives with different alkyl or aromatic residues on the geminal hydroxy bis-
phosphonate by this synthetic pathway. The rearranged phosphonic acid derivative was
the main product (Ruel et al. 1995; Brittelli 1985).
Complex formation with n.c.a. 68Ga was comparable for BPAPD, DOTAPAM or
DOTAZOL in terms of labelling yields and kinetics. Yields between 80 to 95 % were
achieved after 15 min. Complex formation with n.c.a. 177Lu resulted in a quantitative


















Fig. 4 The graph represents the results from the ex vivo organ distribution of the 68Ga- and 177Lu-
complexes of DOTAZOL in percent injected dose per gram
Fig. 5 Whole body scintigraphy 1 h after administration of [177Lu]DOTAZOL. The compound shows strong
accumulation in the bone, and in particular in the high metabolic epiphyseal plates and other joint regions
(the same effect was observed for the 68Ga-bisphosphonates)
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apatite for the DOTA-α-OH-bisphosphonate compared to DOTA-α-H-bisphosphonate,
which could be further verified in ex vivo and in in vivo experiments. The DOTA pami-
dronate conjugate [68Ga]DOTAPAM (SUV = 4.5 ± 0.2) showed a higher accumulation in
bone compared to the DOTA bisphosphonate conjugate [68Ga]BPAPD (SUV = 3.2 ±
0.3). This proves the expectation that bisphosphonates containing an α-OH group have
an enhanced accumulation on calcified surfaces, like it is discussed in the common lit-
erature. This leads to an almost doubled bone to blood ratio of 7.6 for [68Ga]DOTAPAM
compared to 3.7 for [68Ga]BPAPD. According to previous studies nitrogen-containing
hydroxy bisphosphonates, especially N-heteroaromatic compounds showed an en-
hanced accumulation on bone. The N-heteroaromatic [68Ga]DOTAZOL showed the best
bone to blood ratio of 11.5 and the best bone uptake (SUV = 5.4 ± 0.6) of all tested
bisphosphonates. The overall skeleton accumulation is very similar for all tracers and it
is comparable to that of [18F]NaF, which is in the range of 40 to 50 %ID.
In rats, all DOTA-based bisphosphonates showed PET images of good quality, which
proves their potential as useful skeletal imaging agents. Basically, bisphosphonates are
known to have a long biological half-life in bone. Since DOTA compounds are easy to
label with β- or α-particle emitters like 177Lu, 213Bi or 225Ac, the tracers discussed in
this paper seemed to be excellently suitable for bone targeted radionuclide therapy.
Therefore, we investigated the biodistribution of the best performed compound with its
177Lu analogous. [177Lu]DOTAZOL showed to have the same skeletal retention, but a
faster blood clearance. The kidney uptake was found to be higher for the 177Lu-com-
plex (1.78 ± 0.13 %ID/g) compared to the 68Ga-complex (0.24 ± 0.02 %ID/g). The re-
sults show that the incorporated radionuclide can have a significant influence on the
organ distribution. The reason therefore can be explained by the different complexes,
the six-dentate 68Ga-complex and the seven-dentate 177Lu-complex. The overall change
of the Me(III)-DOTA-moiety may contribute to the pharmacology of the whole mol-
ecule. Nevertheless, the compound DOTAZOL maybe very well suited for the use of the
theranostic pair 68Ga/177Lu to both detect and treat bone diseases which has to be fur-
ther evaluated in dosimetry and tumor uptake studies.
It is also to mention that [68Ga]EDTMP was evaluated by Fellner et al. (2011) and
Mitterhauser et al. (2007) as a PET imaging agent against [18F]NaF. They concluded
that [68Ga]EDTMP has no advantage in image quality. In fact it was distinctly inferior
and EDTMP is not suited as a bone targeting complexing agent for 68Ga3+ , in contrast
to 153Sm3+ or 177Lu3+. Yousefnia et al. recently compared [177Lu]EDTMP against
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macrocyclic conjugates of bisphosphonates. In contrast to the well-known bone target-
ing compounds [18F]NaF and [177Lu/153Sm]EDTMP DOTA-bisphosphonates can be
used as a therapy and imaging agents, when labelled with β- and positron emitting
radio metals.Conclusion
In conclusion, α-OH and N-heteroaromatic bisphosphonates like DOTAZOL are more dif-
ficult to synthesize than simple α-H-bisphosphonates like BPAPD but show a significant
improved accumulation in the skeleton. The new DOTA conjugated bisphosphonates
allow for high radiochemical yields (80–95 %) with 68Ga after 15 min and a quantitative
radiochemical yields with 177Lu after 30 min. Data from in vivo small animal PET/SPECT
and ex vivo biodistribution showed fast blood clearance, low uptake in soft tissue and a
high accumulation in the skeleton with [68Ga/177Lu]DOTAZOL being the best leading
compound. In order to avoid problems with the nomenclature of this compound, in the
following this molecule will be referred to also as [68Ga/177Lu]MM1.MZ.Methods
General methods
Chemicals and solvents were commercially available in analytical, HPLC or grade and
were purchased from Sigma-Aldrich (TraceSELECT®) or Merck KGaA. DOTA-NHS
ester (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccini-
midyl ester)) was synthesized according to a procedure described in the literature (Li
et al. 2006) or purchased from Chematech (Dijon, France). Proton nuclear magnetic
resonance (1H-NMR) spectra were recorded on a Bruker 300, 31P-NMR were recorded
on a Bruker 600. Mass spectra were recorded on Agilent Technologies 6130 Quadru-
pole LC/MS spectrometer with ESI as ion source in positive or negative modes or on a
Finnigan MAT-95 spectrometer with FD as ion source. TLC analyses were carried out
with silica on aluminium foil (Merck). Radio-TLC analysis of labelled compounds were
performed also with silica on aluminium foil (Merck) and a Canberra Packard Instant
Imager. For HPLC and radio-HPLC a Waters-system 1525 with an UV- and a radio-
detector (Berthold Technologies, Germany) was used. Radioactivity of samples were
measured with an Aktivimeter Isomed 2010, MED (Nuklear-Medizintechnik Dresden
GmbH). Radioactivity in tissue samples was determined by using a Wallac WIZARD2
automatic gamma counter (Perkin Elmer, Germany). N.c.a. 177Lu was provided by ITG
(Garching, Germany) as LuCl3 in 0.05 M HCl. N.c.a.
68Ga was obtained from a 68Ge/
68Ga generator system (Eckert & Ziegler). [18F]NaF was purchased from DKFZ
(Deutsches Krebsforschungszentrum, Heidelberg, Germany).Synthesis of DOTAPAM
Pamidronate was synthesized according to a description by (Kieczykowski et al. 1995;
Widler et al. 2002). 4.85 g (54.3 mmol) β-alanine was dissolved in 25 mL of methane-
sulfonic acid. 4.45 g (54.3 mmol) phosphorous acid was added and 10 mL (115 mmol)
phosphorus trichloride was added slowly under vigorous stirring at 75 °C. The reaction
mixture was kept under Argon atmosphere for 12 h at 75 °C. After cooling to room
Meckel et al. EJNMMI Radiopharmacy and Chemistry  (2016) 1:14 Page 10 of 14temperature, 50 g of crushed ice was added under vigorous stirring. The aqueous solution
was heated for 12 h under reflux. After cooling to room temperature conc. aquaous
NaOH was added until the formation of a white precipitate was observed. The mixture
was stored in a fridge for 5 h to complete precipitation and filtered, washed with cold
water and recrystallized from boiling water. Precipitation was initiated by adding ethanol.
The white solid (5.3 g, 69 %) was filtered, washed with EtOH and dried in an oven at 60 °
C. 1H-NMR (D2O/NaOD, 300 MHz): δ 2.30 (m, 2H), 3.34 (t, JH = 6.8 Hz, 2H).
31P-NMR
(D2O/NaOD, 162.05 MHz): δ 17.7 (s, 2P). ESI-MS(-) m/z: calculated 234.07 found 234.10
[M-H]+, ESI-MS(+) m/z: calculated 235.07; found 258.0 [M +Na]+.
DOTABP was synthesized according to a describtion by Ogawa et al. (2009). Twenty
five (25) mg (0.11 mmol) pamidronate was dissolved in 1 mL 0.1 M Na2CO3 in water.
38 mg (0.05 mmol) DOTA-NHS-ester was dissolved in 0.5 mL deionized water and
added to the pamidronate solution. The reaction solution was kept at 40 °C on a
thermo shaker for 24 h. The pH was checked periodically and small amounts of aque-
ous Na2CO3 were used to keep the pH between 8 and 9. The crude mixture was puri-
fied initially by preparative HPLC (Phenomenex Synergy Hydro-RP 80, 10 μ, 250 ×
30 mm, H2O + 0.1 % TFA). In the second step the crude product was purified further
to remove DOTA impurities by solid phase extraction (SPE). An aqueous solution of
the compound was passed over a silica NH2-phase (Merck LiChroprep NH2). After
washing with water/methanol/water the product was eluted with H2O +2 % TFA. After
lyophilisation 4.5 mg (14.5 %) of a white solid was obtained. 1H-NMR (D2O/NaOD,
300 MHz): δ 2.0–2.3 (b, 8H, cyclen-CH2), 2.0–2.33 (b, 2H,-CH2-), 2.9–3.5 (b, 8H,
cyclen-CH2), 2.9–3.5 (b, 2H,-CH2-), 3.74 (bs, 8H, -CH2-CO).
31P-NMR (D2O/NaOD,
162.05 MHz): δ 18.3 (s, 2P). ESI-MS(+) m/z: calculated 621.18 found 1243.3 [2 M +
H]+, 622.1 [M +H+], 311.6 [M + 2H]2+.
Synthesis of DOTAZOL
1-(benzyl acetate) 4-(ethyl acetamide)-imidazole (2)
One (1) g (6.53 mmol) ω-N-acetylhistamine (1) was dissolved in 50 mL dry DMF. 4.4 g
(13 mmol) ceasium carbonate was added. The solution was stirred under argon atmosphere
and ice cooling. Benzyl bromoacetate (2.2 g; 13 mmol) was dissolved in 50 mL dry DMF
and added slowly to the imidazole solution. The mixture was allowed to warm to room
temperature and stirred for 12 h. Charcoal was added and the solids were filtered off. After
removing the solvents under reduced pressure, the crude red residue was recrystallized
from ethyl acetate to obtain 1.14 g (58 %) pale yellow crystals. 1H-NMR (CDCl3, 300 MHz):
δ 1.97 (s, 3H, CH3-CO), 2.76 (t, JH = 6.3 Hz, 2H, CH2-CH2), 3.53 (q, JH = 6.0 Hz, 2H, CH2-
CH2), 4.70 (s, 2H, N-CH2-CO), 5.22 (s, 2H, Bn-CH2-CO), 6.53 (bs, 1H, NH), 6.75 (d, JH =
1.3 Hz, imidazole-H), 7.39 (m, 5H, benzyl), 7.44 (d, JH = 1.3 Hz, 1H, imidazole-H). ). ESI-
MS(+) m/z: calculated 301.14 found 302.3 [M+H]+, 603.2 [2 M+H]+.
1-(1-hydroxy-ethane-1,1-bis(phosphonic acid)) 4-(ethyl amine)-imidazole (4)
Three hundred (300) mg (1 mmol) of (2) was dissolved in 20 mL of dry MeOH. Pd/C
(10%w) was added and stirred under hydrogen atmosphere (5 bar) for 12 h. After re-
moving the solvents the hydrogenated product (3) was weighted to determine yield
(208 mg, 98 %). The acid (3) was used without further purification in the next step.
One (1) mL methanesulfonic acid and 164 mg (2 eq.) phosphorous acid was added.
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added slowly under argon atmosphere. After 12 h the reaction mixture was cooled
down to room temperature and 2 mL of iced water was added. The aqueous solution
was heated for 24 h under reflux. Charcoal was added and the solution was filtered.
After cooling to room temperature concentrated aquaous NaOH was added until the
formation of a white precipitate was observed. The mixture was stored in a fridge over-
night to complete precipitation and filtered, washed with cold water and recrystallized
from boiling water to obtain 88.6 mg (28 %) of a white solid. 1H-NMR (D2O/NaOD,
300 MHz): δ 2.46 (m, 2H, CH2-CH2), 2.66 (m, 2H, CH2-CH2), 4.28 (m, 2H, N-CH2-
phosponate), 6.89 (s, 1H, imidazole-H), 7.54 (s, 1H, imidazole-H). 31P-NMR (D2O/
NaOD, 162.05 MHz): δ 14.4. ESI-MS(+) m/z: calculated 315.04 found 316.05 [M +H]+,
338.04 [M +Na]+
DOTAZOL (5)
To 15.75 mg (0.05 mmol) (4) in 1 mL water, triethylamine (TEA) was added drop wise
until all solids were dissolved. Thirty-eight (38) mg (0.05 mmol) DOTA-NHS-ester was
dissolved in 0.5 mL water and added to the bisphosphonate solution (Ogawa et al.
2009). The reaction solution was kept at 50 °C on a thermo shaker for 24 h. The pH
was checked periodically and small amounts of aqueous TEA were used to keep the pH
between 8 and 9. The crude mixture was purified initially by preparative HPLC (Phe-
nomenex Synergy Hydro-RP 80, 10 μ, 250 × 30 mm, solvent: H2O + 0.1 % TFA). In the
second step the crude product was purified further to remove DOTA impurities by
solid phase extraction (SPE). An aqueous solution of the compound was passed over a
silica NH2-phase (Merck LiChroprep NH2). After washing with water/methanol/water
the product was eluted with H2O + 2 % TFA. After lyophilisation 5.6 mg (15.7 %) of a
white solid was obtained. 1H-NMR (D2O/NaOD, 300 MHz): δ 2.42 (m, 2H, CH2-CH2),
2.61 (m, 2H, CH2-CH2), 2.9–3.5 (b, 16H, cyclen-CH2), 3.75 (bs, 8H, -CH2-CO), 4.55 (m,
2H, N-CH2-phosponate), 7.28 (s, 1H, imidazole-H), 8.54 (s, 1H, imidazole-H).
31P-
NMR (D2O/NaOD, 162.05 MHz): δ 14.3. ESI-MS(+) m/z: calculated 701.2 found 702.5
[M +H]+, 351.1 [M + 2H]2+.
Radiolabelling with n.c.a. 68Ga, 177Lu and quality control
N.c.a. 68Ga was obtained in 400 μL acetone/HCl by cationic post processing from a
68Ge/68Ga generator system eluted with 0.1 M HCl (Brittelli 1985; Zhernosekov et al.
2007). The labelling itself was performed by adding 500 μL sodium acetate buffer
(0.5 M, pH = 4) and 25 nmol ligand to the 68Ga containing solution. The mixture was
heated at 98 °C under moderate shaking on a thermo shaker for 15 min. Subsequently
the solution was diluted to 5 mL with water and passed over a weak anion exchanger
cartridge (25 mg, Merck LiChroprep NH2). After washing with 1 mL water the purified
product was eluted with 2 mL PBS. Radiochemical yields and purities were determined
by radio-TLC (Merck silica, solvent: acetone/acetylacetone/HCl, 10/10/1) and radio-
HPLC (Merck Chromolite RP-18e 100 × 4.6 mm, gradient: H2O to acetonitrile). To dis-
criminate between free 68Ga and 68Ga-bisphosphonates a small aliquot of the prod-
uct solution was incubated for 1 min with a 0.25 M DFO (Desferoxamine)
solution. DFO complexes unlabelled 68Ga instantly and shows a longer retention
time on RP-18 HPLC (see Additional file 1: Figure S1). 1 GBq n.c.a. 177LuCl3
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20 nmol of the ligand DOTAZOL in 1 mL of a 0.25 M sodium acetate solution and
heated for 30 min at 98 °C. Radiochemical yields were determined by radio-TLC
using sodium citrate (0.1 M, pH = 4) as the solvent.
Adsorption experiments on apatite
Hydroxy apatite (HAP) (20 mg, Sigma-Aldrich, reagent grade powder) was incubated
in isotonic saline (1 mL) for 24 h. Fifty (50) μL of the 68Ga-labelled bisphosphonate so-
lution was added to the HAP suspension. After vortexing for 10 s, the suspension was
incubated for 10 min at room temperature under moderate shaking on a thermo
shaker. The supernatant was removed by centrifugation. The HAP fraction was washed
with saline (0.5 mL) and the 68Ga radioactivity in the combined liquids and that of the
HAP fraction were measured. 68Ga-complex binding to HAP was determined as per-
centage of 68Ga absorbed to HAP (N = 5) (Fellner et al. 2011).Animal studies
Male Wistar rats were purchased from Charles River Laboratories Inc weighting 140–
220 g. The animal experiments were carried out in consensus to institutional guide-
lines, the German welfare regulations and the European Convention for the Protection
of Vertebrate Animals for Experimental and other Scientific Purposes.Small animal PET and SPECT
Small animal PET and SPECT imaging was performed under general anesthesia
with isoflurane inhalation. The rats were positioned supine in a Siemens Focus 120
μPET (Mediso nanoScan SPECT)and 15 to 18 MBq of the radio tracers (100 MBq
for 177Lu-SPECT) were administrated in 0.5 mL isotonic saline intravenously (i.v.)
via the tail vein. Images were reconstructed to OSEM 2D and files were processed using
PMOD software (TAC) and Amine software (MIP). SPECT images were reconstructed
using ROVER software.Biodistribution
For each compound five animals were injected with 8 to 10 MBq of the radio tracers in
0.5 mL PBS/isotonic saline via the tail vein. The rats were sacrificed at 60 min and 1 d p.i.
and organs of interest were excised, weighed and the radioactivity was measured decay cor-
rected on a gamma counter. The amount of organ accumulation is expressed in SUV (stan-
dardised uptake value) by the equitation: SUV= (activity per g tissue)/(injected activity) x
body weight. Activity in the skeleton was calculated as percentage of injected dose (%ID) by
the following equitation: %ID(skeleton) = femur(%ID/g) x skeleton weight (g). The skeleton
weight of the rats were calculated using: skeleton weight = 9.66 + 0.0355 x body weight
(Vachal et al. 2006).Statistical analysis
All data were expressed as mean ± SD. Groups were compared using the t-test. All statis-
tical tests were two tailed, with a P-value of less than 0.05 representative for significance.
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Additional file 1: Figure S1. Quality control of [68Ga]DOTAZOL by means of cross checked radio-HPLC and radio-
TLC, as a representative of 68Ga-labelled bisphosphonates. A: After 15 min reaction time. B: After SPE purification.
A(HPLC): Rt([
68Ga]DOTAZOL) = 0.6 min. (88 %), Rt([
68Ga]DFO) = 4.1 min. (12 %). B(HPLC): Rt([
68Ga]DOTAZOL) = 0.6 min.
(98 %). A(TLC): Rf([
68Ga]DOTAZOL) = 0.1 (85 %), Rf([
68Ga]acetylacetonate) = 0.9 (15 %). B(TLC): Rf([
68Ga]DOTAZOL) = 0.1
(99 %). Control(TLC): Rf([
68Ga] acetylacetonate) = 0.9 (99 %). Figure S2. Radio-HPLC of [177Lu]DOTAZOL on a Zorbax
300SB-C18 9,4 × 250 mm 5 μ, A = 100 mM TEAP pH = 2,24, isocratic flow: 1 ml/min. Figure S3. Radio-HPLC of urine
and blood samples after administration of [177Lu]DOTAZOL. The HPLC method used for analysing the Lu-177
complexes is also suitable for the Ga-68 complexes of DOTA-Bisphosphonates. The Ga-68 complexes showed a
different retention time based on the different character of the DOTA complex. This is also known for other
DOTA-Compounds like DOTATOC or DOTATATE. Figure S4. Radio-HPLC of [68Ga]DOTAZOL on a Zorbax 300SB-C18
9,4 × 250 mm 5 μ, A = 100 mM TEAP pH = 2,24, isocratic flow: 1 ml/min. (DOCX 742 kb)
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